within Pharmacolibrary.Drugs.ATC.V;

model V09GX01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.23333333333333334,
    adminDuration  = 600,
    adminMass      = 0.074,
    adminCount     = 1,
    Vd             = 0.00013000000000000002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Thallium (201Tl) chloride is a radioactive diagnostic agent used primarily in nuclear medicine for myocardial perfusion imaging to detect areas of ischemia or infarct in the heart. It is not used as a therapeutic drug. Its use has declined due to the advent of newer agents such as technetium-99m compounds, but it is still approved and occasionally used today for specific diagnostic indications.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetics in healthy adults. Thallium-201 chloride is administered intravenously for scintigraphy. Detailed human pharmacokinetics are sparsely reported in the literature; values below are based on data referenced in review articles and package inserts.</p><h4>References</h4><ol><li><p>Thomas, SR, et al., &amp; Castronovo, FP (2005). Radiation-absorbed dose from 201Tl-thallous chloride. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> 46(3) 502–508. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15750165/&quot;>https://pubmed.ncbi.nlm.nih.gov/15750165</a></p></li><li><p>Sehweil, A, et al., &amp; Omar, YT (1988). The optimum time for tumour imaging with thallium-201. <i>European journal of nuclear medicine</i> 13(10) 527–529. DOI:<a href=&quot;https://doi.org/10.1007/BF00256629&quot;>10.1007/BF00256629</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3371374/&quot;>https://pubmed.ncbi.nlm.nih.gov/3371374</a></p></li><li><p>Higuchi, T, et al., &amp; Bengel, FM (2011). Stable delineation of the ischemic area by the PET perfusion tracer 18F-fluorobenzyl triphenyl phosphonium after transient coronary occlusion. <i>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</i> 52(6) 965–969. DOI:<a href=&quot;https://doi.org/10.2967/jnumed.110.085993&quot;>10.2967/jnumed.110.085993</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21571789/&quot;>https://pubmed.ncbi.nlm.nih.gov/21571789</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end V09GX01;
